Search

Your search keyword '"Mah, Jean"' showing total 605 results
Start Over Author "Mah, Jean"
605 results on '"Mah, Jean"'

152. Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children

Author

Hathout, Yetrib, primary, Conklin, Laurie S., additional, Seol, Haeri, additional, Gordish-Dressman, Heather, additional, Brown, Kristy J., additional, Morgenroth, Lauren P., additional, Nagaraju, Kanneboyina, additional, Heier, Christopher R., additional, Damsker, Jesse M., additional, van den Anker, John N., additional, Henricson, Erik, additional, Clemens, Paula R., additional, Mah, Jean K., additional, McDonald, Craig, additional, and Hoffman, Eric P., additional

Published
2016
Full Text
View/download PDF

153. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD)

Author

Goselink, Rianne J. M., primary, Schreuder, Tim H. A., additional, Mul, Karlien, additional, Voermans, Nicol C., additional, Pelsma, Maaike, additional, de Groot, Imelda J. M., additional, van Alfen, Nens, additional, Franck, Bas, additional, Theelen, Thomas, additional, Lemmers, Richard J., additional, Mah, Jean K., additional, van der Maarel, Silvère M., additional, van Engelen, Baziel G., additional, and Erasmus, Corrie E., additional

Published
2016
Full Text
View/download PDF

154. Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015

Author

Tawil, Rabi, primary, Mah, Jean K., additional, Baker, Scott, additional, Wagner, Kathryn R., additional, Ryan, Monique M., additional, Corbett, Alistair, additional, van Engelen, Baziel, additional, McNamara, Stephen, additional, Rasko, John, additional, Raykar, Veena, additional, Sacconi, Sabrina, additional, Tapscott, Stephen J., additional, Tawil, Rabi, additional, and Watts, Alan, additional

Published
2016
Full Text
View/download PDF

156. A multinational study on motor function in early-onset FSHD.

Author

Mah, Jean K., Jia Feng, Jacobs, Marni B., Duong, Tina, Carroll, Kate, de Valle, Katy, Carty, Cara L., Morgenroth, Lauren P., Guglieri, Michela, Ryan, Monique M., Clemens, Paula R., Thangarajh, Mathula, Webster, Richard, Smith, Edward, Connolly, Anne M., McDonald, Craig M., Karachunski, Peter, Tulinius, Mar, Harper, Amy, and Cnaan, Avital

Published
2018
Full Text
View/download PDF

157. Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.

Author

Schwartz, Carolyn E., Grover, Stephanie A., Powell, Victoria E., Noguera, Austin, Mah, Jean K., Mar, Soe, Mednick, Lauren, Banwell, Brenda L., Alper, Gulay, Rensel, Mary, Gorman, Mark, Waldman, Amy, Schreiner, Teri, Waubant, Emmanuelle, and Yeh, E. Ann

Subjects
MULTIPLE sclerosis in children, PEDIATRICS, DISEASE prevalence, REGRESSION analysis, QUALITY of life, SELF-efficacy
Abstract

Background: Adherence to disease-modifying therapies (DMTs) in pediatric multiple sclerosis (MS) is not well understood. We examined the prevalence and risk factors for poor adherence in pediatric MS. Methods: This cross-sectional study recruited youth with MS from 12 North American pediatric MS clinics. In addition to pharmacy-refill data, patients and parents completed self-report measures of adherence and quality of life. Additionally, patients completed measures of self-efficacy and well-being. Factor analysis and linear regression methods were used. Results: A total of 66 youth (mean age, 15.7 years) received MS DMTs (33% oral, 66% injectable). Estimates of poor adherence (i.e. missing >20% of doses) varied by source: pharmacy 7%, parent 14%, and patient 41%. Factor analysis yielded two composites: adherence summary and parental involvement in adherence. Regressions revealed that patients with better self-reported physical functioning were more adherent. Parents were more likely to be involved in adherence when their child had worse parentreported PedsQL School Functioning and lower MS Self-Efficacy Control. Oral DMTs were associated with lesser parental involvement in adherence. Conclusion: Rates of non-adherence varied by information source. Better self-reported physical functioning was the strongest predictor of adherence. Parental involvement in adherence was associated with worse PedsQL School Functioning and lower MS Self-Efficacy-measured confidence in controlling MS. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

158. The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities.

Author

Yi Wei, McCormick, Anna, MacKenzie, Alex, O'Ferrall, Erin, Venance, Shannon, Mah, Jean K., Selby, Kathryn, McMillan, Hugh J., Smith, Garth, Oskoui, Maryam, Hogan, Gillian, McAdam, Laura, Mabaya, Gracia, Hodgkinson, Victoria, Lounsberry, Josh, Korngut, Lawrence, and Campbell, Craig

Subjects
NEUROMUSCULAR disease diagnosis, NEUROMUSCULAR diseases, CLINICAL trials, REPORTING of diseases, DUCHENNE muscular dystrophy, MYOTONIA atrophica, PEDIATRICS, SPINAL muscular atrophy, SURVEYS, THERAPEUTICS
Abstract

Introduction: Patient registries serve an important role in rare disease research, particularly for the recruitment and planning of clinical trials. The Canadian Neuromuscular Disease Registry was established with the primary objective of improving the future for neuromuscular (NM) patients through the enablement and support of research into potential treatments. Methods: In this report, we discuss design and utilization of the Canadian Neuromuscular Disease Registry with special reference to the paediatric cohort currently enrolled in the registry. Results: As of July 25, 2017, there are 658 paediatric participants enrolled in the registry, 249 are dystrophinopathies (229 are Duchenne muscular dystrophy), 57 are myotonic dystrophy participants, 98 spinal muscular atrophy participants and 65 are limb girdle muscular dystrophy. A total of 175 patients have another NM diagnosis. The registry has facilitated 20 clinical trial inquiries, 5 mail-out survey studies and 5 other studies in the paediatric population. Discussion: The strengths of the registry are discussed. The registry has proven to be an invaluable tool to NM disease research and has increased Canada's visibility as a competitive location for the conduct of clinical trials for NM therapies. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

162. Management of multiple sclerosis in adolescents – current treatment options and related adherence issues

Author

Mah, Jean

Subjects
Adolescent Health, Medicine and Therapeutics
Abstract

Jean K Mah1, Jennifer E Thannhauser21Division of Neurology, Department of Pediatrics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada; 2Division of Applied Psychology, Faculty of Education, University of Calgary, Calgary, Alberta, CanadaAbstract: Multiple sclerosis (MS) is a progressive inflammatory demyelinating disorder of the central nervous system that is increasingly recognized in children and adolescents. This realization comes with additional concerns about existing therapeutic options and the impact of the disease on health-related outcomes of adolescents with MS. This five-part review provides an update on management strategies relevant to the pediatric MS population. The first section gives an overview on the epidemiology and natural history of early onset MS. The second section outlines currently available MS treatments, including medications during acute relapses and long-term immunomodulatory therapies. The third section highlights adherence issues pertaining to MS, including the challenges uniquely faced by adolescents. The fourth section provides a summary of research into quality of life and psychosocial consequences of pediatric onset MS. Attention is drawn to the grief experience of affected adolescents and the importance of peer relationships. Finally, the family resilience framework is presented as a conceptual model to facilitate optimal adaptation of adolescents with MS. Healthcare professionals can promote resilience and treatment adherence by ensuring that these individuals and their families are sufficiently informed about available MS treatments, providing instrumental support for managing potential medication side effects, and addressing age-appropriate developmental needs.Keywords: multiple sclerosis, disease-modifying therapies, adolescents, treatment adherence

Published
2010

166. 225th ENMC international workshop:: A global FSHD registry framework, 18–20 November 2016, Heemskerk, The Netherlands

Author

Ferreira, Verònica Alonso, Attarian, Sharam, Berardinelli, Angela, Bogard, Betsy, Dawkins, Hugh, van Engelen, Baziel, Evangelista, Teresinha, van der Graaf, Kees, Heatwole, Chad, Kinoshita, June, Van der Maarel, Silvère, Mah, Jean, Mul, Karlien, van Rens, Jacqui, Richiardi, Armelle, Roxburgh, Richard, Sacconi, Sabrina, Tawil, Rabi, Tupler, Rossella, van der Meij-Kim, Diana, Voet, Nicole, and Vohánka, Stanislav

Published
2017
Full Text
View/download PDF

168. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

Author

Campbell, Craig, McMillan, Hugh J., Mah, Jean K., Tarnopolsky, Mark, Selby, Kathryn, McClure, Ty, Wilson, Dawn M., Sherman, Matthew L., Escolar, Diana, and Attie, Kenneth M.

Subjects
BODY composition, CELL receptors, COMPARATIVE studies, DRUG administration, DOSE-effect relationship in pharmacology, DUCHENNE muscular dystrophy, GROWTH factors, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, RESEARCH, WALKING, EVALUATION research, RANDOMIZED controlled trials, TREATMENT effectiveness, BLIND experiment, THERAPEUTICS
Abstract

Introduction: ACE-031 is a fusion protein of activin receptor type IIB and IgG1-Fc, which binds myostatin and related ligands. It aims to disrupt the inhibitory effect on muscle development and provide potential therapy for myopathies like Duchenne muscular dystrophy (DMD).Methods: ACE-031 was administered subcutaneously every 2-4 weeks to DMD boys in a randomized, double-blind, placebo-controlled, ascending-dose trial. The primary objective was safety evaluation. Secondary objectives included characterization of pharmacokinetics and pharmacodynamics.Results: ACE-031 was not associated with serious or severe adverse events. The study was stopped after the second dosing regimen due to potential safety concerns of epistaxis and telangiectasias. A trend for maintenance of the 6-minute walk test (6MWT) distance in the ACE-031 groups compared with a decline in the placebo group (not statistically significant) was noted, as was a trend for increased lean body mass and bone mineral density (BMD) and reduced fat mass.Conclusion: ACE-031 use demonstrated trends for pharmacodynamic effects on lean mass, fat mass, BMD, and 6MWT. Non-muscle-related adverse events contributed to the decision to discontinue the study. Myostatin inhibition is a promising therapeutic approach for DMD. Muscle Nerve 55: 458-464, 2017. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

169. Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada.

Author

Yea, Carmen, Bitnun, Ari, Robinson, Joan, Mineyko, Aleksandra, Barton, Michelle, Mah, Jean K., Vajsar, Jiri, Richardson, Susan, Licht, Christoph, Brophy, Jason, Crone, Megan, Desai, Shalini, Hukin, Juliette, Jones, Kevin, Muir, Katherine, Pernica, Jeffrey M., Pless, Robert, Pohl, Daniela, Rafay, Mubeen F., and Selby, Kathryn

Subjects
ACUTE flaccid paralysis, HEALTH outcome assessment, CEREBROSPINAL fluid, ENTEROVIRUSES, MAGNETIC resonance imaging, DIAGNOSIS
Abstract

We describe the presenting features and long-term outcome of an unusual cluster of pediatric acute flaccid paralysis cases that occurred in Canada during the 2014 enterovirus D68 outbreak. Children (n = 25; median age 7.8 years) presenting to Canadian centers between July 1 and October 31, 2014, and who met diagnostic criteria for acute flaccid paralysis were evaluated retrospectively. The predominant presenting features included prodromal respiratory illness (n = 22), cerebrospinal fluid lymphocytic pleocytosis (n = 18), pain in neck/back (n = 14) and extremities (n = 10), bowel/bladder dysfunction (n = 9), focal central gray matter lesions found in all regions of the spinal cord within the cohort (n = 16), brain stem lesions (n = 8), and bulbar symptoms (n = 5). Enterovirus D68 was detectable in nasopharyngeal specimens (n = 7) but not in cerebrospinal fluid. Acute therapies (corticosteroids, intravenous immunoglobulins, plasmapheresis) were well tolerated with few side effects. Fourteen of 16 patients who were followed beyond 12 months post onset had neurologic deficits but showed ongoing clinical improvement and motor recovery. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

175. 209 - Results of an International Corneal Confocal Microscopy (CCM) Consortium: A Pooled Multicentre Analysis of the Concurrent Diagnostic Validity of CCM to Identify Diabetic Polyneuropathy in Type 2 Diabetes Mellitus

Author

Perkins, Bruce A., Lovblom, Leif E., Bril, Vera, Edwards, Katie, Pritchard, Nicola, Russell, Anthony, Pacaud, Danièle, Romanchuk, Kenneth, Mah, Jean, Boulton, Andrew, Jeziorska, Maria, Marshall, Andrew, Shtein, Roni M., Pop-Busui, Rodica, Feldman, Eva L., Lentz, Stephen I., Tavakoli, Mitra, Efron, Nathan, and Malik, Rayaz A.

Published
2016
Full Text
View/download PDF

176. 59 - Results of an International Corneal Confocal Microscopy (CCM) Consortium: A Pooled Multicentre Analysis of the Concurrent Diagnostic Validity of CCM to Identify Diabetic Polyneuropathy in Type 1 Diabetes Mellitus

Author

Perkins, Bruce A., Lovblom, Leif E., Bril, Vera, Edwards, Katie, Pritchard, Nicola, Russell, Anthony, Pacaud, Danièle, Romanchuk, Kenneth, Mah, Jean, Boulton, Andrew, Jeziorska, Maria, Marshall, Andrew, Shtein, Roni M., Pop-Busui, Rodica, Feldman, Eva L., Lentz, Stephen I., Tavakoli, Mitra, Efron, Nathan, and Malik, Rayaz A.

Published
2016
Full Text
View/download PDF

179. Management of multiple sclerosis in adolescents – current treatment options and related adherence issues

Author

Mah,Jean, Thannhauser,Jennifer E, Mah,Jean, and Thannhauser,Jennifer E

Abstract

Jean K Mah1, Jennifer E Thannhauser21Division of Neurology, Department of Pediatrics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada; 2Division of Applied Psychology, Faculty of Education, University of Calgary, Calgary, Alberta, CanadaAbstract: Multiple sclerosis (MS) is a progressive inflammatory demyelinating disorder of the central nervous system that is increasingly recognized in children and adolescents. This realization comes with additional concerns about existing therapeutic options and the impact of the disease on health-related outcomes of adolescents with MS. This five-part review provides an update on management strategies relevant to the pediatric MS population. The first section gives an overview on the epidemiology and natural history of early onset MS. The second section outlines currently available MS treatments, including medications during acute relapses and long-term immunomodulatory therapies. The third section highlights adherence issues pertaining to MS, including the challenges uniquely faced by adolescents. The fourth section provides a summary of research into quality of life and psychosocial consequences of pediatric onset MS. Attention is drawn to the grief experience of affected adolescents and the importance of peer relationships. Finally, the family resilience framework is presented as a conceptual model to facilitate optimal adaptation of adolescents with MS. Healthcare professionals can promote resilience and treatment adherence by ensuring that these individuals and their families are sufficiently informed about available MS treatments, providing instrumental support for managing potential medication side effects, and addressing age-appropriate developmental needs.Keywords: multiple sclerosis, disease-modifying therapies, adolescents, treatment adherence

Published
2010

180. DKA and thrombosis

Author

Burzynski, Jeff, Ho, Josephine, Pacaud, Daniele, and Mah, Jean

Abstract

Josephine Ho and associates (1) report an unfortunate case of a 6-year-old girl with diabetic ketoacidosis (DKA) and thromboembolic stroke. Although the authors do a credible job of describing the [...]

Published
2005

183. The CNDR: Collaborating to Translate New Therapies for Canadians

Author

Korngut, Lawrence, primary, Campbell, Craig, additional, Johnston, Megan, additional, Benstead, Timothy, additional, Genge, Angela, additional, MacKenzie, Alex, additional, McCormick, Anna, additional, Biggar, Douglas, additional, Bourque, Pierre, additional, Briemberg, Hannah, additional, O'Connell, Colleen, additional, Dojeiji, Suzan, additional, Dooley, Joseph, additional, Grant, Ian, additional, Hogan, Gillian, additional, Johnston, Wendy, additional, Kalra, Sanjay, additional, Katzberg, Hans D., additional, Mah, Jean K., additional, McAdam, Laura, additional, McMillan, Hugh J., additional, Melanson, Michel, additional, Selby, Kathryn, additional, Shoesmith, Christen, additional, Smith, Garth, additional, Venance, Shannon L., additional, and Wee, Joy, additional

Published
2013
Full Text
View/download PDF

184. Neurological Registry Data Collection Methods and Configuration

Author

Smith, Eric E., primary, Warner, Janet, additional, Johnston, Megan, additional, Atwood, Kristin, additional, Hall, Ruth, additional, Mah, Jean K., additional, Maxwell, Colleen, additional, Fortin, Claire Marie, additional, Lowerison, Mark, additional, Kapral, Moira K., additional, Noonan, Vanessa K., additional, Pfister, Ted, additional, MacKean, Gail, additional, Casselman, Lisa, additional, Pringsheim, Tamara, additional, Jette, Nathalie, additional, and Korngut, Lawrence, additional

Published
2013
Full Text
View/download PDF

185. Evaluation of Neurological Patient Registries

Author

Mah, Jean K., primary, Warner, Janet, additional, Hall, Ruth, additional, Smith, Eric E., additional, Steeves, Thomas, additional, Donner, Elizabeth, additional, Marriott, James, additional, Johnston, Megan, additional, Lowerison, Mark, additional, de Robles, Paula, additional, Noonan, Vanessa K., additional, Mehina, Essie, additional, Jette, Nathalie, additional, Pringsheim, Tamara, additional, and Korngut, Lawrence, additional

Published
2013
Full Text
View/download PDF

186. Neurological Registry Quality Control and Quality Assurance

Author

Marriott, James, primary, Noonan, Vanessa K., additional, Donner, Elizabeth, additional, Lowerison, Mark, additional, Lam, Darren, additional, Day, Lundy, additional, Warner, Janet, additional, Smith, Eric E., additional, Mah, Jean K., additional, de Robles, Paula, additional, Jette, Nathalie, additional, Johnston, Megan, additional, Pringsheim, Tamara, additional, and Korngut, Lawrence, additional

Published
2013
Full Text
View/download PDF

187. Registry Data Storage and Curation

Author

Johnston, Megan, primary, Campbell, Craig, additional, Hayward, Rachel, additional, Lowerison, Mark, additional, Noonan, Vanessa K., additional, Pfister, Ted, additional, Maxwell, Colleen, additional, Fortin, Claire Marie, additional, Smith, Eric E., additional, Mah, Jean K., additional, Kapral, Moira K., additional, Jette, Nathalie, additional, Pringsheim, Tamara, additional, and Korngut, Lawrence, additional

Published
2013
Full Text
View/download PDF

189. The International Incidence and Prevalence of Neurological Diseases – Do We Really Know How Common Neurological Conditions Are? Challenges in Interpreting International Epidemiological Studies (IN6-2.002)

Author

Jette, Nathalie, primary, Pringsheim, Tamara, additional, Day, Lundy, additional, De Robles, Paula, additional, Fiest, Kirsten, additional, Hamilton, Mark, additional, Hogan, David, additional, Korngut, Lawrence, additional, Kwon, Churl-Su, additional, Lam, Darren, additional, Mah, Jean, additional, Marrie, Ruth-Ann, additional, Maxwell, Colleen, additional, Metcalfe, Amy, additional, Oskoui, Maryam, additional, Patten, Scott, additional, Pearson, Dawn, additional, Reid, Aylin, additional, Smith, Eric, additional, Steeves, Thomas, additional, Svenson, Larry, additional, Wiebe, Samuel, additional, and Dykeman, Jonathan, additional

Published
2013
Full Text
View/download PDF

191. The International Incidence and Prevalence of Neurological Diseases – Do We Really Know How Common Neurological Conditions Are? Challenges in Interpreting International Epidemiological Studies (P04.235)

Author

Jette, Nathalie, primary, Pringsheim, Tamara, additional, Day, Lundy, additional, De Robles, Paula, additional, Fiest, Kirsten, additional, Hamilton, Mark, additional, Hogan, David, additional, Korngut, Lawrence, additional, Kwon, Churl-Su, additional, Lam, Darren, additional, Mah, Jean, additional, Marrie, Ruth-Ann, additional, Maxwell, Colleen, additional, Metcalfe, Amy, additional, Oskoui, Maryam, additional, Patten, Scott, additional, Pearson, Dawn, additional, Reid, Aylin, additional, Smith, Eric, additional, Steeves, Thomas, additional, Svenson, Larry, additional, Wiebe, Samuel, additional, and Dykeman, Jonathan, additional

Published
2013
Full Text
View/download PDF

192. Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.

Author

Boca, Simina M., Nishida, Maki, Harris, Michael, Rao, Shruti, Cheema, Amrita K., Gill, Kirandeep, Seol, Haeri, Morgenroth, Lauren P., Henricson, Erik, McDonald, Craig, Mah, Jean K., Clemens, Paula R., Hoffman, Eric P., Hathout, Yetrib, and Madhavan, Subha

Subjects
TREATMENT of Duchenne muscular dystrophy, BIOMARKERS, DUCHENNE muscular dystrophy, HISTORY of medicine, BLOOD serum analysis, METABOLIC profile tests, DISEASE progression, PATIENTS
Abstract

Serum metabolite profiling in Duchenne muscular dystrophy (DMD) may enable discovery of valuable molecular markers for disease progression and treatment response. Serum samples from 51 DMD patients from a natural history study and 22 age-matched healthy volunteers were profiled using liquid chromatography coupled to mass spectrometry (LC-MS) for discovery of novel circulating serum metabolites associated with DMD. Fourteen metabolites were found significantly altered (1% false discovery rate) in their levels between DMD patients and healthy controls while adjusting for age and study site and allowing for an interaction between disease status and age. Increased metabolites included arginine, creatine and unknown compounds at m/z of 357 and 312 while decreased metabolites included creatinine, androgen derivatives and other unknown yet to be identified compounds. Furthermore, the creatine to creatinine ratio is significantly associated with disease progression in DMD patients. This ratio sharply increased with age in DMD patients while it decreased with age in healthy controls. Overall, this study yielded promising metabolic signatures that could prove useful to monitor DMD disease progression and response to therapies in the future. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

193. Polio-Like Illness Associated With Outbreak of Upper Respiratory Tract Infection in Children.

Author

Crone, Megan, Tellier, Raymond, Wei, Xing-Chang, Kuhn, Susan, Vanderkooi, Otto G., Kim, Jong, Mah, Jean K., and Mineyko, Aleksandra

Subjects
CENTRAL nervous system infections, POLIOVIRUS, ENTEROVIRUS diseases, JUVENILE diseases, PEDIATRICS
Abstract

Poliomyelitis is a historically devastating neurological complication of poliovirus infection. Poliovirus vaccines have decreased the incidence of poliomyelitis to 209 global cases in 2014, with new cases of acute flaccid myelitis primarily associated with nonpolio enteroviruses. Recently, during outbreaks of enterovirus D68 throughout North America and Europe, cases of acute flaccid myelitis have been reported, suggesting another nonpolio enterovirus associated with acute flaccid myelitis. The authors describe 3 patients diagnosed with acute flaccid myelitis during a province-wide outbreak of enterovirus D68 with the virus detected in 2 of the patients. Given the significant morbidity associated with acute flaccid myelitis and potential for nonpolio enterovirus to cause outbreaks, prompt identification and notification of public health authorities are warranted. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

195. A Population-Based Study of Dystrophin Mutations in Canada

Author

Mah, Jean K., primary, Selby, Kathryn, additional, Campbell, Craig, additional, Nadeau, Amelie, additional, Tarnopolsky, Mark, additional, McCormick, Anna, additional, Dooley, Joseph M., additional, Kolski, Hanna, additional, Skalsky, Andrew J., additional, Smith, R. Garth, additional, Buckley, David, additional, Ray, Peter N., additional, and Yoon, Grace, additional

Published
2011
Full Text
View/download PDF

196. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study

Author

Banwell, Brenda, primary, Bar-Or, Amit, additional, Arnold, Douglas L, additional, Sadovnick, Dessa, additional, Narayanan, Sridar, additional, McGowan, Melissa, additional, O'Mahony, Julia, additional, Magalhaes, Sandra, additional, Hanwell, Heather, additional, Vieth, Reinhold, additional, Tellier, Raymond, additional, Vincent, Thierry, additional, Disanto, Giulio, additional, Ebers, George, additional, Wambera, Katherine, additional, Connolly, Mary B, additional, Yager, Jerome, additional, Mah, Jean K, additional, Booth, Fran, additional, Sebire, Guillaume, additional, Callen, David, additional, Meaney, Brandon, additional, Dilenge, Marie-Emmanuelle, additional, Lortie, Anne, additional, Pohl, Daniela, additional, Doja, Asif, additional, Venketaswaran, Sunita, additional, Levin, Simon, additional, MacDonald, E Athen, additional, Meek, David, additional, Wood, Ellen, additional, Lowry, Noel, additional, Buckley, David, additional, Yim, Conrad, additional, Awuku, Mark, additional, Cooper, Pamela, additional, Grand'Maison, François, additional, Baird, J Burke, additional, Bhan, Virender, additional, and Marrie, Ruth Ann, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results